In the comparison of the efficacy of bimekizumab and secukinumab in the treatment of plaque psoriasis, one case of ulcerative colitis was reported in each treatment arm, suggesting that drugs inhibiting IL-17 may induce or worsen IBD (Reich et al., 2021b). Here, IL17A is linked to inflammatory bowel disease.